XTL Biopharmaceuticals Ltd. (H2K2)
Market Closed
4 Jul, 20:00
XMUN 
€
1. 06
+0.02
+1.92%
€
9.79M Market Cap
- P/E Ratio
0% Div Yield
0 Volume
0 Eps
€ 1.04
Previous Close Day Range
1.06 1.06
Year Range
0.94 2.7
Want to track H2K2 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
H2K2 closed yesterday higher at €1.06, an increase of 1.92% from Thursday's close, completing a monthly increase of 1.92% or €0.02. Over the past 12 months, H2K2 stock lost -42.39%.
H2K2 is not paying dividends to its shareholders.
The last earnings report, released on Jun 03, 2024, exceeded the consensus estimates by 0.09%. On average, the company has surpassed earnings expectations by 0.03%, based on the last three reports.
XTL Biopharmaceuticals Ltd. has completed 2 stock splits, with the recent split occurring on Feb 10, 2017.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).
H2K2 Chart
Loading, please wait...
XTL Biopharmaceuticals Ltd. (H2K2) FAQ
What is the stock price today?
The current price is €1.06.
On which exchange is it traded?
XTL Biopharmaceuticals Ltd. is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is H2K2.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0%.
What is its market cap?
As of today, the market cap is 9.79M.
Has XTL Biopharmaceuticals Ltd. ever had a stock split?
XTL Biopharmaceuticals Ltd. had 2 splits and the recent split was on Feb 10, 2017.
XTL Biopharmaceuticals Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Noam Band CEO | XMUN Exchange | US98386D3070 ISIN |
| IL Country | 10 Employees | - Last Dividend | 10 Feb 2017 Last Split | 1 Sep 2005 IPO Date |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Contact Information
Address: 5 Badner Street
Phone: 972 3 611 6600
Website: https://www.xtlbio.com
2025 © Marketlog. All Rights Reserved.
